Market Newsdesk

VANCOUVER, British Columbia, Jan. 05, 2021 (GLOBE NEWSWIRE) — A.I.S. Resources Limited (TSX: AIS, OTCQB: AISSF) (the “Company” or “AIS”) announces that the initial results from the Deep Ground Penetrating Radar of the Fosterville-Toolleen Gold Property have been received. Response anomalies are evident in the preliminary results with early output provided by LozaRadar in a colored 2D section set out below. The strong near surface response is yet to be fully interpreted, however, early data analysis suggests the existence of a shallow channel development that may be gold bearing.

Phillip Thomas CEO commented, “Denis Walsh, our Chief Geologist, and I are delighted with the initial results achieved so far and the structures shown by the radar. Fosterville hosts three distinct mineralization styles: (a) refractory gold in fine-grained arsenopyrite (b) visible gold hosted in fault-controlled quartz-carbonate veins associated with stibnite mineralization, and (c) vein-hosted visible gold with little or no associated stibnite. We are seeking to identify styles or variations of (b) or (c) from the data interpreted so far. This is an important phase in the exploration program and drilling will prove up our mineralisation model.”

Ordovician basement contact is thought to be represented in part by the aquamarine-grey/yellow contrast depicted in the section below. This means that any reefs or quartz veins containing gold are shallow and less than 25 metres. This is one of the five lines of radar completed. The remaining data is expected to be received in January 2021.

Fig. 1 – https://www.globenewswire.com/NewsRoom/AttachmentNg/cff7d0cf-482a-4334-b9aa-75b9b504cc70 

The primary target on the Toolleen tenement EL006001 is Ordovician aged meta-sediments common in the Fosterville area. The setting of EL006001 is located within a favorable structural framework within the Bendigo Zone which hosts the Fosterville deposit. Rocks of the approximately the same age also mapped in various positions across EL006001. Fosterville is principally related to a series of NNW trending reverse faults in the hanging wall of the regional Redesdale Fault whilst 12km to the east Toolleen, is located in the hanging wall of the Heathcote-Mount William fault zone understood from government seismic data to be a significant west dipping thrust.

AIS Resources’ Chief Geologist Denis Walsh will further assess the outputs integrating topographical data, available surface and subsurface geological understanding (magnetic and gravity data) and location of reported nuggets to extract the maximum value out of the data to progress exploration for gold deposits. It is expected that understanding the radar results of the survey will significantly enhance further exploration program results.

A soil geochemistry program utilizing a low detection partial extraction method suited to areas of shallow cover is being planned over EL006001.

Fig. 2 – https://www.globenewswire.com/NewsRoom/AttachmentNg/3fdef4f6-431e-4937-95cb-34064193586d

Regional gravity images of EL006001 show a significant gravity feature that does not show on the magnetic image, indicating a different source rock type than the highly magnetic and highly dense units to the east in the footwall of the Heathcote-Mount William fault zone. The regional gravity dataset is based on broadly spaced stations so a more detailed ground gravity program is planned to confirm the regional and local picture. Subsequently, a drilling program is planned to test for primary and secondary sources of nuggets, results from soil geochemistry and features identified in the radar geophysics and gravity surveys.

Fig. 3 – https://www.globenewswire.com/NewsRoom/AttachmentNg/565ec3c3-1e70-433d-954c-1b8faa1785b0

Technical information in this news release has been reviewed and approved by Phillip Thomas, BSc Geol MAIG who is a Qualified Person under the definitions established by the National Instrument 43-101.

About A.I.S. Resources Limited

A.I.S. Resources Limited is a publicly traded investment issuer listed on the TSX Venture Exchange focused on precious and base metals exploration. AIS’s value add strategy is to acquire prospective exploration projects and enhance their value by better defining the mineral resource with a view to attracting joint venture partners and enhancing the value of its portfolio. The Company is managed by a team of experienced geologists, with a track-record of successful capital markets achievements. In November 2020, AIS received TSX-V approval to acquire the New South Wales Yalgogrin Gold Project JV, the Fosterville-Toolleen Gold Project and the Kingston Gold Project in Victoria Australia.

Phillip Thomas
CEO

A.I.S. Resources ltd.

For further information, please contact:
Phillip Thomas, Chief Executive Officer
Tel: +1-747-200-9412
Email: [email protected] 
Or
Martyn Element, Executive Chairman
Tel: +1-604-220-6266
Email: [email protected]
Website: www.aisresources.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

ADVISORY:

This press release contains forward-looking statements. More particularly, this press release contains statements concerning the anticipated use of the proceeds of the Private Placement. Although the Corporation believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. The
intended use of the proceeds of the Private Placement by the Corporation might change if the board
of directors of the Corporation determines that it would be in the best interests of the Corporation to deploy the proceeds for some other purpose. The forward-looking statements contained in this press release are made as of the date hereof and the Corporation undertakes no obligations to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

George V. Hager, Jr.
Retires as CEO and Director

Board of Directors Appoints Current Chairman, Robert H. Fish as New CEO

KENNETT SQUARE, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) — Genesis Healthcare, Inc. (Genesis, or the Company) (NYSE:GEN), one of the largest post-acute care providers in the United States, announced today that George V. Hager, Jr. has decided to retire as the Company’s Chief Executive Officer (CEO) and Director. Genesis’ Board of Directors has appointed the Company’s current Chairman of the Board, Robert (“Bob”) H. Fish as CEO, effective today, January 5, 2021. Bob will remain Chairman of the Board.

Mr. Fish, a member of the Genesis Board of Directors since 2013 and Chairman since 2017, has extensive experience as a healthcare company executive, including significant experience in the long-term care industry. Mr. Hager will continue in a senior advisory role to the Company’s Board of Directors.

“The Board and I would like to thank George for 28 years of unwavering leadership and tireless commitment and service to the Company, its employees, patients, residents and families, and to the entire post-acute industry,” said Mr. Fish. “We are pleased that George will serve as a senior advisor to me and the Board of Directors, assisting with the transition, ongoing restructuring efforts and continued advocacy for the Company and the industry.”

“We are fortunate to have Bob step in as a leader with significant experience both inside and outside of Genesis. He brings expertise and continuity essential to Genesis as we continue to navigate the impact of COVID-19 and explore avenues to strengthen the Company financially,” said Mr. Hager. “It has been my honor to serve and lead this Company over the last 17 years. I would like to thank the senior management team as well as our Center leaders and caregivers for their dedication and commitment to Genesis and our patients, residents and families. I am also proud to have had the opportunity to bring our founder, Michael R. Walker’s, vision to fruition these many years,” continued Mr. Hager.

“I am pleased to become Genesis’ Chief Executive Officer and am excited to lead the Company as we look to emerge from the pandemic and navigate to recovery,” said Mr. Fish. “I look forward to sharing my vision and direction for the Company in the coming months.”

Mr. Fish has a long history with Genesis and its predecessor companies Genesis HealthCare Corp. and Genesis Health Ventures, Inc. He has served on its current Board of Directors since 2013 when he joined Skilled Healthcare Group, Inc. as CEO until its merger with Genesis in 2015. Additionally, from 2003 to 2007, he served as Lead Director of Genesis HealthCare Corp., and from 2002 to 2003 he served as Chairman and Chief Executive Officer of Genesis Health Ventures, Inc. During his career, Mr. Fish has served as Chairman, President or CEO of several other healthcare companies. Most recently, from 2018 to July 2020, he served as President, CEO and Director of Quorum Health Corporation, a publicly held operator of general acute care hospitals and outpatient services. From 2008 to 2012, he served as Chairman of REACH Medical Holdings, a regional air medical transport company, from 2005 to 2006 he served as Executive Chairman of Coram, Inc., a large home infusion provider. Previously, Mr. Fish served as President and Chief Executive Officer of St. Joseph Health System—Sonoma County and Valleycare Health System, both regional hospital systems in Northern California.

About Genesis HealthCare

Genesis HealthCare is a holding company with subsidiaries that, on a combined basis, comprise one of the nation’s largest post-acute care companies, providing services to more than 325 skilled nursing facilities and assisted/senior living communities in 24 states nationwide. Genesis subsidiaries also supply rehabilitation therapy to approximately 1,100 healthcare providers in 44 states, the District of Columbia and China.  References made in this release to “Genesis,” “the Company,” “we,” “us” and “our” refer to Genesis Healthcare, Inc. and each of its wholly-owned companies. Visit our website at www.genesishcc.com.

Genesis Healthcare Contact:


Investor Relations
610-925-2000

HOUSTON, Jan. 05, 2021 (GLOBE NEWSWIRE) — C-Bond Systems (the “Company” or “C-Bond”) (OTC: CBNT), a nanotechnology solutions company, today preannounced record revenue in excess of $400,000 for the fourth quarter of 2020, and record annual revenue for 2020. The revenue will exceed 2019 by at least 25%, with growth trends accelerating during the last two quarters, a trend the Company anticipates continuing.

In early 2020 as the COVID-19 pandemic began to unfold, management made the strategic decision to pivot its business, thereby positioning itself for partnership opportunities to sell a broader range of nano-products, including disinfectants.

In the fourth quarter of 2020, the Company received two $100,000 purchase orders under previously announced distribution agreements for its EPA registered MB-10 Tablets and C-Bond nanoShield windshield strengthener, as well as orders for its C-Bond Secure glass strengthening primer and window film mounting solution, and C-Bond BRS (ballistic-resistant system) product for building security.

“On the heels of announcing that we generated record revenue of more than $250,000 for Q3 2020, we are proud to preannounce record revenue of more than $400,000 for Q4 2020,” stated Scott R. Silverman, Chairman and CEO of C-Bond.

“While the first and second quarters of 2020 were extremely challenging due to the evolving COVID-19 global pandemic, the pivot we made in our business combined with significant new customer relationships helped drive revenue growth across both our Transportation Solutions Group and Safety Solutions Group in the latter half of the year,” continued Silverman. “We expect these agreements to continue to propel revenue growth throughout 2021.”

About C-Bond

C-Bond Systems, Inc. (OTC: CBNT) is a Houston-based advanced nanotechnology company and marketer of the patented C-Bond technology, developed in conjunction with Rice University and independently proven to significantly strengthen glass in key automotive and structural applications. The Company’s Transportation Solutions Group sells C-Bond nanoShield, a liquid solution applied directly to automotive windshields, sold through distributors. The Company’s Safety Solutions Group sells ballistic-resistant glass solutions directly to private enterprises, schools, hospitals and government agencies. The Company also sells disinfection products, including MB-10 Tablets. For more information, please visit our website: www.cbondsystems.com, Facebook: https://www.facebook.com/cbondsys/ and Twitter: https://twitter.com/CBond_Systems.

Forward-Looking Statements

Statements in this press release about our future expectations, including the likelihood that revenue growth trends will continue; the likelihood that these customer agreements will continue to propel revenue growth throughout 2021; constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, C-Bond’s ability to raise capital; the Company’s ability to successfully commercialize its products; the effect of the COVID-19 global pandemic on the Company’s ability to operate; the Company’s ability to source materials; as well as other risks. Additional information about these and other factors may be described in the Company’s filings with the Securities and Exchange Commission (“SEC”) including its Form 10-K filed on March 25, 2020, its Forms 10-Q filed on November 16, 2020, August 14, 2020, and May 15, 2020, and in future filings with the SEC. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Contact:

Allison Tomek
C-Bond Systems
6035 South Loop East
Houston, TX 77033
[email protected]

Brokers and Analysts:
Chesapeake Group
410-825-3930
[email protected]

BOSTON, Jan. 05, 2021 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will participate in the H.C. Wainwright Virtual BioConnect 2021 Conference to be held January 11-14, 2021 and the LifeSci Advisors 10th Annual Corporate Access Event to be held January 6-14, 2021.

The virtual LifeSci Advisors event presentation will be live at 12:00 pm EST on January 8, 2021 from the Albireo Media and Investors page ir.albireopharma.com and the H.C. Wainwright fireside chat will be available beginning Monday, January 11, 2021 also at ir.albireopharma.com. Both sessions will be archived and available for replay on Albireo’s website for two weeks following the events.  

About Albireo

Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo’s lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. For more information on Albireo, please visit www.albireopharma.com.

Media & Investor contacts:

Colleen Alabiso, 857-356-3905, [email protected]
Hans Vitzthum, LifeSci Advisors, LLC., 857-272-6177

SAN FRANCISCO, Jan. 05, 2021 (GLOBE NEWSWIRE) — The number one acne brand at Sephora, Peace Out Skincare, is launching its award-winning Acne Serum in Canada today. The serum follows the Acne Healing Dot as the second Peace Out product certified by Health Canada to treat the medical condition of acne. Health Canada’s stringent vetting process includes consumer studies that validate the efficacy of a product.

Peace Out’s Acne Serum is created from a proprietary blend of salicylic acid, niacinamide, vitamin C and zinc to create a gentle, yet powerful treatment to reduce acne and improve the look and feel of your skin. Intended for application twice daily and used in tandem with Peace Out Skincare’s Acne Dots or Peace Out Pores, the combo gives a one-two punch to current pimples while preventing further breakouts without irritating the skin.

“Following the approval of our Acne Treatment Dot, we’re grateful for the additional validation from Health Canada with its certification of Peace Out Skincare’s Acne Serum. The serum was developed as a response to my own lifelong issues with acne,” shares Peace Out Skincare Founder and CEO, Enrico Frezza. “If I need a more effective treatment that doesn’t irritate my skin, then so do our Peace Out skin-champs around the world.”

The global brand entered Sephora Canada in May of last year, selling a selection of its skincare products. The Canadian market responded enthusiastically by selling out of products three times over. Peace Out Acne Serum will launch on Sephora.ca today, January 5, and in physical stores January 15th retailing for $45 CAD.

Peace Out Skincare


Beauty-technology leader, Peace Out Skincare is committed to creating first-to-market, innovative solutions for everyday skin problems. Launched in 2017, the brand is known for combining cutting edge delivery systems with clean, effective, high-quality ingredients. Peace Out Skincare celebrates their ‘skin champ’ community by promoting acne positivity and skin inclusivity.

Media Contact

Stephanie Kraeutler
The Lead PR
[email protected]
212.584.5668

BEIJING, Jan. 05, 2021 (GLOBE NEWSWIRE) — BlueCity Holdings Limited (“BlueCity” or the “Company”) (NASDAQ: BLCT), a world’s leading online LGBTQ platform, today announced the appointment of Mr. Weiru Chen as a new independent director to its board of directors (the “Board”), effective immediately. Mr. Zhe Wei has concurrently resigned from his positions as a director and a member of the compensation committee and nominating and corporate governance committee of the Board.

After the changes, the Board will continue to consist of five members, four of whom are independent directors. The compensation committee will consist of Ms. Rong Lu, Mr. Baoli Ma and Mr. Weiru Chen, with Ms. Rong Lu as the chairperson. The nominating and corporate governance committee will consist of Mr. Baoli Ma, Ms. Wenjie Wu and Mr. Weiru Chen, with Mr. Baoli Ma as the chairperson.

Mr. Baoli Ma, BlueCity’s Founder, Chairman and Chief Executive Officer, stated: “We are excited to welcome Mr. Weiru Chen to join our Board. We believe his extensive background in corporate governance, strategic management and industry expertise will be of great value to BlueCity. We look forward to working closely with him and benefiting from his valuable insights and extensive experience. Meanwhile, on behalf of the Board and everyone at BlueCity, I thank Mr. Zhe Wei for his significant contribution to the Company during his tenure on the Board. We wish him all the best in his future endeavors.”

Mr. Weiru Chen is an associate professor of strategy at China Europe International Business School (CEIBS). He has served as executive director of the Internet Industry Research Center and chief strategic officer of Alibaba Cainiao Logistic Network between August 2017 and July 2020. Prior to joining CEIBS, he served as an assistant professor of strategy at INSEAD Business School from 2003 to 2011. Mr. Chen’s research is centered on firms’ technological innovation, platform strategy, and digital transformation. Mr. Chen has also served as an independent director of several public companies, including TAL Education Group (NYSE: TAL) since June 2015, Dian Diagnostics Group (SHE: 300244) since August 2017, Country Garden Services Holdings Company Limited (HK: 06098) since February 2018 and FangDD Network Group Ltd. (Nasdaq: DUO) since November 2019. Mr. Chen received a bachelor’s degree from National Taiwan University in Taiwan in 1993, a master’s degree from TamKang University in 1996 and a Ph.D. in Management from Purdue University in 2003.

About BlueCity

BlueCity (NASDAQ: BLCT) is a world-leading online LGBTQ platform providing a full suite of services that fosters connections and enhance the wellbeing of the LGBTQ community through its portfolio of brands. BlueCity’s mobile app Blued enables users to conveniently and safely connect with each other, express themselves and access professional health-related and family planning consulting services. Available in 13 languages, it has more than 58 million registered users worldwide and is the largest online LGBTQ community in China, India, Korea, Thailand and Vietnam. BlueCity’s portfolio of brands also includes Finka, a leading gay social networking app for a younger generation in China, and LESDO, a leading lesbian social networking app in China.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” and similar statements. Among other things, business outlook and quotations from management in this announcement, as well as BlueCity’s strategic and operational plans, contain forward-looking statements. BlueCity may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about BlueCity’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement. Further information regarding these risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. All information provided in this press release and in the attachments is current as of the date of the press release, and the Company does not undertake any obligation to update such information, except as required under applicable law.

For more information, please contact:

In China:
BlueCity Holdings Limited
Ms. Lingling Kong
Investor Relations Director
Phone: +86 10-5876-9662
Email: [email protected]

The Blueshirt Group
Ms. Susie Wang
Phone: +86 138-1081-7475
Email: [email protected]

In the United States:
The Blueshirt Group
Ms. Julia Qian
Phone: +1 973-619-3227
Email: [email protected]

NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in three virtual investor conferences in January 2021.

Details of the events are as follows:

• 10^th Annual LifeSci Partners Corporate Access Event: The company will host virtual one-on-one meetings during the conference on Wednesday, January 6 through Friday, January 8 and Monday, January 11 through Thursday, January 14, 2021.
• 2021 CTIC 5^th Healthcare Investment Digital Summit: The company will present on Saturday, January 9, 2021, at 8:00 p.m. EST.
• H.C. Wainwright Virtual BioConnect Conference: The company’s presentation will be available for on-demand viewing on Fortress’ website beginning Monday, January 11, 2021, at 6:00 a.m. EST and will remain available on the Events page under the News & Media section of Fortress’ website: www.fortressbiotech.com for approximately 30 days following the presentation.

About Fortress Biotech

Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company that was ranked in Deloitte’s 2019 and 2020 Technology Fast 500™, annual rankings of the fastest-growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors, based on percentages of fiscal year revenue growth over three-year periods. Fortress is focused on acquiring, developing and commercializing high-potential marketed and development-stage drugs and drug candidates. The company has five marketed prescription pharmaceutical products and over 25 programs in development at Fortress, at its majority-owned and majority-controlled partners and at partners it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is driven by a world-class business development team that is focused on leveraging its significant biopharmaceutical industry expertise to further expand the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including Alexion Pharmaceuticals, Inc., AstraZeneca, City of Hope, Fred Hutchinson Cancer Research Center, InvaGen Pharmaceuticals Inc. (a subsidiary of Cipla Limited), St. Jude Children’s Research Hospital and Nationwide Children’s Hospital. For more information, visit www.fortressbiotech.com.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words “we”, “us” and “our” may refer to Fortress individually or together with one or more partner companies, as dictated by context. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; risks relating to the timing of starting and completing clinical trials; our dependence on third-party suppliers; risks relating to the COVID-19 outbreak and its potential impact on our employees’ and consultants’ ability to complete work in a timely manner and on our ability to obtain additional financing on favorable terms or at all; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The information contained herein is intended to be reviewed in its totality, and any stipulations, conditions or provisos that apply to a given piece of information in one part of this press release should be read as applying mutatis mutandis to every other instance of such information appearing herein.

Company Contacts:

Jaclyn Jaffe and William Begien
Fortress Biotech, Inc.
(781) 652-4500
[email protected]

Investor Relations Contact:

Daniel Ferry
LifeSci Advisors, LLC
(617) 430-7576
[email protected]

Media Relations Contact:

Tony Plohoros
6 Degrees
(908) 591-2839
[email protected]

AUSTIN, Texas, Jan. 05, 2021 (GLOBE NEWSWIRE) — Chuy’s Holdings, Inc. (NASDAQ:CHUY) today announced the Company will participate in two investor conferences in January.

On Tuesday, January 12, 2021, the Company will participate in a virtual fireside chat discussion at the 23^rd Annual ICR Conference. Chuy’s discussion will begin at 1:30 PM ET.

On January 19-20, 2021, the Company will also participate in a virtual Jefferies 10^th Annual Winter Restaurant, Foodservice, Gaming, Lodging & Leisure Summit.

About Chuy’s

Founded in Austin, Texas in 1982, Chuy’s owns and operates full-service restaurants across 19 states serving a distinct menu of authentic, made from scratch Tex-Mex inspired dishes. Chuy’s highly flavorful and freshly prepared fare is served in a fun, eclectic and irreverent atmosphere, while each location offers a unique, “unchained” look and feel, as expressed by the concept’s motto “If you’ve seen one Chuy’s, you’ve seen one Chuy’s!”. For further information about Chuy’s, including the nearest location, visit the Chuy’s website at www.chuys.com.

Investor Relations Contact:
Fitzhugh Taylor
203-682-8261
[email protected]